Baumer

Baumer Net Debt / EBITDA

The Net Debt to EBITDA of Baumer (BALM4.SA) as of Nov 15, 2026 is -1.67. In the previous year, Net Debt to EBITDA was -1.77 — a change of -5.98% (higher).

Net Debt / EBITDA

-1.67

YoY

-5.98%

Last updated:

Net Debt to EBITDA of Baumer is 2024 -1.67 . Net Debt to EBITDA of Baumer was 2023 -1.77 . It decreases by -5.98% higher compared to the previous year.

The Baumer Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
4.83 BRL
Jan 1, 2018
4.20 BRL
Jan 1, 2019
1.91 BRL
Jan 1, 2020
-0.76 BRL
Jan 1, 2021
-1.83 BRL
Jan 1, 2022
-0.99 BRL
Jan 1, 2023
-1.77 BRL
Jan 1, 2024
-1.67 BRL
The Baumer Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-1.67-5.98%
-1.77+79.39%
-0.99-46.03%
-1.83+141.71%
-0.76-139.75%
1.91-54.63%
4.20-13.06%
4.83+152.85%
1.91+250.45%
0.55+46.77%
0.37-40.88%
0.63-14.92%
0.74-12.81%
0.85+13.85%
0.74+134.33%
0.32-63.82%
0.88-32.36%
1.30-4,705.41%
-0.03-95.91%
-0.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baumer Stock analysis

What does Baumer do? Baumer SA generates revenue through the sale of medical equipment and solutions across its four business units. The Orthopedic unit produces and sells orthopedic implants and instruments, while the Hospital unit manufactures equipment for hospitals and industries including pharmaceutical, chemical, cosmetic, and food sectors. The Genius unit focuses on biomaterials, and the Brown unit supplies laundry equipment for hospitals, industrial, and hotel settings. The company's subsidiaries, Hospitalar Sul Ltda and Waldsea Investment SA, support its operations as of December 31, 2011. The primary buyers of Baumer SA's products include hospitals, pharmaceutical companies, chemical manufacturers, cosmetic firms, and food industry businesses. Additionally, industrial and hotel sectors purchase the laundry equipment from the Brown unit. The company's technical assistance services for medical apparatus also contribute to its revenue stream. Baumer SA's business model relies on direct sales of its specialized equipment and solutions to healthcare and industrial clients. The firm's product portfolio spans orthopedic care, hospital infrastructure, biomaterials, and laundry systems, catering to both medical and non-medical industrial applications. This diversified approach allows the company to serve multiple segments within the health and industrial markets. Baumer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baumer stock

Net Debt to EBITDA of Baumer is -1.67 in 2024.

Net Debt to EBITDA of Baumer changed from -1.77 to -1.67, representing a -5.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Baumer since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Baumer with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Baumer

All Key Metrics — Baumer